Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Thanks for the post heldnova... hornet just told me about that tax loss strategy and it's. Ice to hear that people actually do that.
Steve,
That would have been the correct conclusion of ADXS was like $50 and fell to like $40.....
ADXS Market Cap is near frigging cash value.... THERE IS NO EXPLANATION FOR THIS!
Good catch ubmmg.... now Hornet's post about $7.50 Puts got a big bang to it
Hornet, they have the opportunity to cover / execute the Jan 2018 options right now at a profit.... so why wait until expiration date?
Dude that short interest history is 2015... why don't you look at the year 2017?
Historically, ADXS has fluctuated with short interest between 7 million to 10 million....
IMO, that 3 million shorts were retail who covered and are done shorting cuz risk-reward makes no sense shorting at $3 for ADXS...
That other 7 million short cartel is pointing towards that they are not interested in profits.... they are more interested in keeping ADXS suppressed....
Today is soooooo slow..... come'on 4pm already
"Massive dilution is as plausible as any other scenario. Maybe more so."
So would be class action lawsuit, I will be the first one in line
There are biotechs that jump on little insignificant stuff....
Then there is ADXS, that went even more down after approval and validation of its LM technology hitting the market thru AT-014...
ADXS fundamentals point clearly point for it to be atleast double digits stock on the low ball valuation, yet here we are, near CASH ON HAND....
This is pure nonsense, and Management is POS for not destroying whoever is suppressing ADXS Price
Thanks for the link Chemist. I like the following statement:
"During this period, 30 medicines received a conditional marketing authorisation. None had to be revoked or suspended."
Thanks for the link oakrock, good article by hovacre!
"Any other/more interpretations (+ or -)?"
I would think the next short interest would be higher, they used a lot of might in the past few days to suppress the rise of AT-014 conditional approval....
Thanks blue.
Thanks for the long explanation. This 30 day rule must be killing day traders right?
Is that 30 day limit for when you completely close out a stock position? Or any kind of tax loss sale?
Blue what the the wash out rule mean? Where this wouldn't be applicable?
I read about washout but didn't understand it...
Anyone watching ADRO's fall today?
"Green! Hope no body got suckered to sell!"
I got suckered to buy more on today's red....
Anything I single digits is a bargain for ADXS, comparing $2s and $3s will be meaningless when ADXS hits its fair value
ADXS SUPER COILED SPRING:
None of the following is reflected in ADXS current price, and what will happen when all gets reflected at the same time?
1. AMGEN Partnership
2. SELLAS Partnership
3. Stendhal Partnership
4. Four Cancer Franchises:
4a. ADXS-AXAL
4b. ADXS-PSA
4c. ADXS-NEO
4d. ADXS-HOT
4e. ADXS looking to partner for ADXS-HER2 to save cash burn
5. AT-014 conditional approval (a proof that ADXS LM technology finally hit the market!)
6. Plan for EU application (part 1, manufacturing facility, of application already cleared)
7. Pending EU Partnership
8. New CMO and possibly, New CEO
Half million volume in like 35 minutes of trading....
Even though ADXS is red, I like the buying demand it's created (thus resulting in half million volume)
Nice Article on ADXS explains what the analyst (Cantor) is expecting:
Specifically, I like the following statement:
"Meanwhile, 2018 will also likely bring a new CEO leader at the helm to take over in interim CEO Anthony Lombardo’s stead along with a CMO."
Source:
https://www.smarteranalyst.com/2017/12/26/bull-bets-533-upside-potential-advaxis-inc-adxs-shares/
Good post blue. Another question what's the real agenda of those 7 million shorts STILL lurking around...
If they wanted to make profits, now would be the time cuz ADXS market cap is near cash value... and risk-reward to shorting at this level makes no sense
"Analyst predict $3.12 earnings per share by 2022, put a 15 multiple on that and your at almost $50 per share."
15 is a multiple for a company with little to no growth....
Right now, biotech aggregate P/E multiple is 324, so multiply $3.26 by atleast 324, and what is that number?
I hear ya Terry... atleast we moving in the intended direction thru conditional approval... full approval is only one more study away :)
The one thing that can change ADXS big time is ADXS-PSA Combo getting extraordinary results....
Just imagine MERK and AMGEN both taking interest...
And the second best thing could be ADXS-DUAL and NEO results...
Just imagine BMY and AMGEN taking a competing interest....
Thanks Chemist, good post
"The two anal trials were very different populations."
This is a pain the butt to understand...
"Preliminary Stage 1 results from 29 of the planned evaluable patients showed 1 (3.5%) patient had a durable partial response lasting > 6 months (after progression on prior anti-PD-1 therapy) and 7 had stable disease (24%). Disease control rate was 28%. The current Kaplan Meier 6-month PFS estimate is 22%, indicating the trial met the criteria to proceed to Stage 2 of enrollment. "
Does this mean ADXS beat past statistics of 22% in FAWCETT?
Aggregate Short Volume Data Reported to FINRA
Date Short Volume Short Percent
12-21-2017 513,240 59.23%
12-20-2017 601,069. 51.35%
12-19-2017 171,420. 45.75%
"Where is Christmas present from Lombardo?"
We already got the present of ADXS falling hard from $3.50s all thanks to Lombardo's Conference (no pipeline updates)
Thanks for adding on
"Don't all of those conferences have allowances for "late breaking" presentations?"
Yes, March 15, 2018 is Late-Breaking Data Submission Deadline
ADXS Timeline:
Q1-2018
1. Submit EU Application
2. Hire CMO
3. Submit ADXS-NEO IND Amendment
4. Possible Surprise:
EU PARTNERSHIP
Q2-2018
5. ADXS-NEO Initiation (begin dosing)
6. ADXS-DUAL IND
Possible Surprise:
ADXS-PSA in ASCO 2018
And what about AZN? I thought ASXS was done, but conference says to expect train updates with Combo data in 2018 followed by next phase in 2019?
Correction on ASCO:
Listed below is statement from Petit on Conference Call:
ADXS-PSA...
"I can't guarantee when and where, but we are hopeful that the time we will get we might be able to say something at ASCO in mid-year"
Did Petit mean ASCO 2018 or 2019? That I don't know....
Best statement of conference call right before closing remarks:
"We will continue dialogue with potential EU partners while continuing to pursue other business development opportunities to support our business."
ADXS-IND and HOT both starting with non-small lung cancer according to conference call....
Why not target different kinds of cancers so one franchise doesn't compete with another?
Hey Dew, wasn't ADXS getting top results with An*l cancer? Why did ADXS stop it?
Conference Call states stopping of head, neck and anal cancer...
ADXS is gonna bum out on ASCO 2018 (nothing new to show)
February 13, 2018
Abstract Submission Deadline
Mid-April
Abstracts Released
June 1 - June 5, 2018
ASCO Annual Meeting